US 2021/0060102 A1Published application

Cancer therapy with a parvovirus combined with bevacizumab

AssigneesDeutsches Krebsforschungszentrum, Ruprecht-Karls-UniversitäT

InventorsKarsten Geletneky, Jean Rommelaere, Wolfgang Wick, Antje Wick, Michael Dahm

Life of this patent

Estimating the term…

Abstract

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.

Claims8

Dependent claims

Pharmaceutical composition containing (a) a parvovirus in combination with (b) bevazizumab, wherein said parvovirus is 5 H-1 (H-IPV).

Dependencies are inferred from the claim text.

Facts

Application: 16/949,331Filed 26 Oct 2020
Priority: EP 15154629.811 Feb 2015
Published: 4 Mar 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 35/768
Viruses; Subviral particles; Bacteriophages: oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61P 35/00
Antineoplastic agents

Family

Application15/550,354Continuation · filed 10 Aug 2017
Application16/949,331Continuation
US 10,813,959 B2Related patent
US 2018/0028583 A1Published application
US 2021/0060102 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results